Insider · CIK 0001191062
Jay M Moyes
Files at BCDA (BioCardia, Inc.), SINT (Sintx Technologies, Inc.), PBYI (PUMA BIOTECHNOLOGY, INC.). First filing Jun 17, 2025, latest Jun 15, 2026.
Jay M Moyes files SEC Form 4 as director at SINT (Sintx Technologies, Inc.), and also at PBYI (PUMA BIOTECHNOLOGY, INC.), BCDA (BioCardia, Inc.). Since Jun 17, 2025, Jay M Moyes has reported 2 open-market buys worth $14k and 2 open-market sells worth $234k, the latest filed on Jun 15, 2026.
A track record needs three past buys with six months of prices behind them; Jay M Moyes has 2, so none is measured yet.
The newest scored trade: sold $159k of PBYI on Jun 12, 2026, filed Jun 15, 2026, scored 24 (weak), under a 10b5-1 plan. In the last 12 months: 1 buy worth $2,910 and 1 sell worth $159k.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
PBYI: PUMA BIOTECHNOLOGY, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
SINT: Sintx Technologies, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | PUMA BIOTECHNOLOGY, INC. | $159k 22,000 shares | -27% | +139% from low-6% from high | |
| 44Moderate | Sintx Technologies, Inc. | $2,910 1,000 shares | +33% | +70% from low-47% from high | |
| 46Moderate | Sintx Technologies, Inc. | $11k 3,000 shares | - | +120% from low-40% from high | |
| 28Weak | PUMA BIOTECHNOLOGY, INC. | $75k 22,000 shares | -29% | +38% from low-10% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 13, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | 22,000 0.04% of outstanding | $75k | Jun 13, 2025 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Common Stock10b5-1 | +27,000 | $0.00 | $0 | 80,322 | Jun 15, 2026 |
| Jun 12, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -22,000 | $7.22 | $159k | 58,322 | Jun 15, 2026 |
| Feb 23, 2026 | SINT Sintx Technologies, Inc. | POpen-market purchase Common Stock | +1,000 | $2.91 | $2,910 | 4,000 | Feb 25, 2026 |
| Dec 8, 2025 | BCDA BioCardia, Inc. | AGrant or award Stock Option (right to buy)derivative | +12,000 | $0.00 | $0 | 15,573 | Dec 10, 2025 |
| Aug 26, 2025 | SINT Sintx Technologies, Inc. | POpen-market purchase Common Stock | +3,000 | $3.59 | $11k | 3,000 | Aug 27, 2025 |
| Jun 13, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | SOpen-market sale Common Stock10b5-1 | -22,000 | $3.40 | $75k | 53,322 | Jun 17, 2025 |
| Jun 11, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | AGrant or award Common Stock | +27,000 | $0.00 | $0 | 75,322 | Jun 13, 2025 |
| Oct 11, 2024 | BCDA BioCardia, Inc. | AGrant or award Stock Option (right to buy)derivative | +829 | $0.00 | $0 | 3,573 | Oct 16, 2024 |
Questions about Jay M Moyes
Answered from the filings on this page, as of the latest one.
Is Jay M Moyes buying or selling?
In the last 12 months Jay M Moyes reported 1 open-market buy worth $2,910 and 1 open-market sell worth $159k on SEC Form 4; the latest was sold $159k of PBYI on Jun 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Jay M Moyes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jay M Moyes has 2.
Where does Jay M Moyes file Form 4?
Jay M Moyes has filed Form 4 at SINT (Sintx Technologies, Inc.); PBYI (PUMA BIOTECHNOLOGY, INC.); BCDA (BioCardia, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.